Artificial Heart Lung Machines Market Size, Share, By Product Type [Component (Pumps, Cannulas & Tubing Sets, Monitoring Systems, and Others), Function (Oxygenation Support, Blood Circulation, Temperature Regulation, and Others)], Technology (Mechanical Systems, Electromechanical Systems, Computer-Assisted Systems, Miniaturized Systems, and Others), Portability (Stationary Systems, Portable Systems, and Compact Systems), Application (Cardiac Surgery, Lung Transplantation, Acute Respiratory Failure, Pediatric Cardiac Procedures, Emergency Resuscitation, and Others), End User (Hospitals & Clinics, Ambulatory Surgical Centers, Research & Academic Institutions, Military Medical Units, Veterinary Clinics, and Others), and Region - Trends, Analysis, and Forecast till 2035

• 2024 Market Size: USD 394.0 Million
• 2035 Projected Market Size: USD 712.25 Million
• CAGR (2025-2035): 5.6%
• North America: Largest Market in 2024

An artificial heart-lung machine or cardiopulmonary bypass machine is a medical device that mimics the functions of the heart and lungs during open surgeries such as open-heart surgery or lung transplantation and some emergency operations. These systems keep the blood moving, oxygenated, carbon dioxide eliminated, and temperatures maintained, so that patients get life-sustaining support when their heart or lungs are switched off or cannot work effectively.

The market of artificial heart-lung machines is expanding as more people become ill with cardiovascular diseases, more complex surgical procedures are performed, and more sophisticated technologies supporting extracorporeal life support such as ECMO (extracorporeal membrane oxygenation) are used. Increased demand in minimally invasive surgery, pediatric heart care, and the application of portable systems in the emergency and critical care setting are also driving rapid market growth. Furthermore, these machines are becoming safer, more efficient, and accessible to many hospitals and surgical centers due to technological advances in monitoring systems, miniaturized devices, and biocompatible materials.

Artificial Heart Lung Machines Import Data:

HSN Code	Product Description	Origin	Destination	Qty.	Price (USD)
90189093	ACC. OF HEART LUNG MACHINE CUSTOM TUBING PACK- CUSTOM PACK 2C00R1 SHRI BD MET	Mexico	India	PCS 77	40.16
90189093	ACC. OF HEART LUNG MACHINE- RESERVOIR EL2120 4 LITER 120 MICRON 6PK	Mexico	India	PAC 20	62.80
90189093	HEART LUNG MACHINE MODEL HL 20 4 PUMP CONSOLE(3 SINGLE PUMP 1TWIN PUMP) WITH STD ACCESSORIES.	Germany	India	UNT1	38,903.96
90189093	PRE-BYPASS ARTERIAL FILTER (ACCESS. FOR HEART LUNG MACHINE)	China	India	NOS 50	3.96

Artificial Heart Lung Machines Export Data:

HSN Code	Product  Description	Origin	Destination	Qty.	Price (USD)
90189099	HEART LUNG MACHINE AND HYPOTHERMIA MACHINE AND COMPLETE SET OF ACCESSORIES	Nigeria	India	SET 1	43,054.72
90189093	HEART LUNG MACHINE ( MEDICAL INSTRUMENTS)	United States	India	NOS 1	67,253.35
90189093	SARNS 9000 HEART LUNG MACHINE WITH DISPLAY & ACCESSORIES	United Arab Emirates	India	NO S	357.80
90189093	ACC. OF HEART LUNG MACHINE- CUSTOM TUBING PACK SEMI ADULT BATCH NO. 1212	Fiji	India	PCS 10	20.85

Current Industry Dynamics & Insights:

• North America has the largest artificial heart lung machines market share, with almost 36.9%.
• The second-largest and fastest-growing area is Europe, by accounting for 28.3%.
• By product type, component holds the largest share for the artificial heart lung machines market.
• On the account of technology, electromechanical systems are the most widely used artificial heart lung machines in the market.

Drivers and Restraints:

Drivers	Restraints	Opportunities & Trends
Growth in open-heart and transplant surgeries Expansion of pediatric cardiac care Aging global population with higher risk factors	Limited availability in low-income regions Risk of complications (clots, hemolysis, infections) Need for highly trained professionals Strict regulatory requirements	Integration with AI and real-time monitoring Rising investments in healthcare infrastructure Demand for long-term extracorporeal support

Key Drivers:

Rising Prevalence of Cardiovascular Diseases Driving Market Growth

The increasing number of cardiovascular diseases in the global world is one of the main causes of increasing the artificial heart-lung machine market. With ageing populations, heart attacks, valve disorders, and congenital defects on the rise, due to age, obesity, hypertension and sedentary lifestyle, there is a boom in the demand of high-technology support systems to carry out surgery. Regardless of the global cardiovascular burden, artificial heart-lung machines are essential in cardiopulmonary bypass and can be used during open-heart surgery and complication surgeries, as they benefit patient outcomes.

• For instance, according to the data presented by the World Heart Federation in 2023 shows that the number of deaths caused by cardiovascular diseases in the world increased by 60% in 30 years: in 1990, it was 12.1 million, in 2021, it was 20.5 million. This trend is an increase in demand of cardiopulmonary bypass devices, caused by the aging population, sedentary lifestyles, comorbidities that are increasing the need to have more and more complex heart surgeries, which need to be supported by a well-functioning artificial heart-lung machine.

Restraints:

High Cost of Devices and Maintenance Limiting Market Expansion

The major challenge in the artificial heart-lung machine market is the high price of the devices and their maintenance. The machines are costly, need special parts and competent staff to operate, and many hospitals especially in low and middle-income areas are unable to afford them. Moreover, the cost of recurring consumable, service, and upgrade feeds on the healthcare budgets, restricting its usage.

• Counterbalance Statements: Although artificial heart-lung machines have high initial and maintenance costs, technology and increased investments in health care infrastructure are slowly making them less expensive. Companies are working on smaller size, longer life parts and built-in monitoring features that can lower operational costs and can spread these life saving gadgets to more areas in developing economies.

Opportunities & Trends:

Biocompatible Coatings Lowering Clinical Complications in Artificial Heart Lung Machines Market

The AHLM market is changing with the use of enhanced biocompatible materials, including hydrogel or zwitterionic polymer coatings on equipment, such as tubing and oxygenators, among others. Such coatings inhibit clotting of blood and also reduce inflammatory effects through the reduction of platelet and protein adhesions. This results with less complications, less systemic anticoagulants, less dangerous and more efficient assistance in operating and prolonged life support conditions.

• For instance, s study published in Nature Communications in 2024 demonstrated that a superhydrophilic endothelial membrane-mimicking coating (PMPCC-Hep) coated on the surfaces of extracorporeal membrane oxygenators in a pig model increased clot-free and leak-free extracorporeal circulation to more than 15 hours-compared to 4 hours clot-free with uncoated systems and 8 hours with conventional heparin-coated systems. It shows that biocompatible surface engineering can contribute to a higher level of safety and efficiency.

Product type, technology, portability, application, end user, and region are the divisions of the artificial heart lung machines market.

By Product Type:

Component and function are product type on which artificial heart lung machines market is segmented. The component has been the most prevalent artificial heart-lung machines market growth since it is a direct expression of the set of tools and functions that one needs to engage in cardiopulmonary support in the operating room. Its use in hospitals and surgical centers all over the world is a result of the need to have fully operational systems that are trustworthy.

The next most dominant segment is the function segment, which establishes the capabilities of the machines in terms of core functions such as oxygenation, circulation and others. The main requirement of hospitals is machines that can offer multi-purpose and efficient assistance, which guarantee high functionality of systems used on a functional basis.

By Technology:

Based on the technology, the artificial heart lung machines market is divided into mechanical systems, electromechanical systems, computer-assisted systems, miniaturized systems, and others. The electromechanical systems prevail with their accuracy and the combination of developed sensors, providing observability and control in the course of procedures. Such systems strike a balance between mechanical reliability and electronic intelligence and make them more efficient and safe.

Computer-assisted systems come next as more and more digital solutions are being implemented by hospitals to monitor and automate. Their predictive analytics and minimization of human error capability make them a rapidly expanding segment.

• For instance, according to European Association cardiac surgery research, a 2025 survey of 20 cardiac surgery units revealed that compared to traditional manual vacuum-assisted venous drainage (VAVD) systems, automated venous systems demonstrated 98% pressure stability, maintained hemolysis rates below 3%, and responded to alarms in less than 2 seconds. This illustrates the importance of automated (electromechanical) systems to increase the safety and performance of bypass surgeries.

By Portability:

Stationary systems, portable systems, and compact systems, are portability of the artificial heart lung machines market. The stationary systems are leading the market since this is the norm in hospitals and heart centers. They give high-capacity support, which is why they are necessary in major surgeries and long usage applications.

Portable systems are becoming increasingly popular as the second most popular choice as they are capable of aiding patients during an emergency or in transit. They are small enough to be used beyond conventional surgical areas.

By Application:

On the application, artificial heart lung machines market is categorized into cardiac surgery, lung transplantation, acute respiratory failure, pediatric cardiac procedures, emergency resuscitation, and others. Artificial heart-lung machines still find the most common use in cardiac surgery, where the devices play a major role in bypassing the heart and assisting its work during open-heart surgery. This dominance is maintained by the increasing cardiovascular surgery.

Acute respiratory failure comes second since artificial heart-lung machines offer vital life support in cases where lungs fail to work properly. Rising cases of respiratory distress, particularly after the pandemic, have raised the pressure in this respect.

• For instance, According to a 2022 study in Annals of Pediatric Cardiology, 32 pediatric patients (median age: 6 years, weight 20 kg) underwent complex Fontan procedures using CPB with deep hypothermic circulatory arrest. The median CPB time was 125 minutes, DHCA lasted 42 minutes, and there were no operative deaths or major neurological complications, highlighting how CPB remains effective and safe for demanding pediatric cardiac surgeries.

By End User:

Hospitals & clinics, ambulatory surgical centers, research & academic institutions, military medical units, veterinary clinics, and others are end user of the artificial heart lung machines market. The market is dominated by hospitals and clinics since they are the primary providers of complicated cardiovascular and pulmonary surgeries. Their availability of qualified personnel and high-level equipment qualifies them to be the main recipients of artificial heart-lung machines.

The second and most important end-users are ambulatory surgical centers that are triggered by the need to undergo minimal invasive surgery and fast recovery. The fact that they are increasingly adopting advanced equipment increases their contribution in the market.

Regional Insights:

Geographically, the artificial heart lung machines market is studied across North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.

North America: This region is a leader in artificial heart-lung machine market as the country has a well-developed healthcare system, a large proportion of cardiac surgeries, and quick uptake of new medical technologies. The presence of the main manufacturers and research centers is another strong argument in its favor.

Hospitals in the U.S. and Canada face economic constraints and increased healthcare expenses, and smaller hospitals tend to find it difficult to afford to install such expensive equipment. This can restrict its adoption to some regions.

• U.S. Artificial Heart Lung Machines Market Insights:

The U.S. is the dominant nation in this region, with a highly developed structure of special cardiac centers and heavy expenditure on surgical technologies. It is the largest source of market demand due to its tremendous emphasis on sophisticated treatment modalities.

Europe: This is a second largest region within the artificial heart-lung machine market share due to universal healthcare, well-trained medical staff, and prompt utilization of state-of-the-art cardiopulmonary technologies. Germany, France and U.K. are the countries which dominate the number of surgical procedures that need these systems.

Nevertheless, hospitals in the region are confronted by stringent regulatory approval procedures, high operation costs, and inflationary forces. All this can cause delays in acquiring newer, costly systems.

• Germany Artificial Heart Lung Machines Market Insights:

Germany is the most dominant country in Europe as it has great surgical capacity, well developed medical infrastructure and also as it pays much attention to cardiovascular treatment. Its established cardiac surgery programs have continued to market artificial heart-lung machines.

Asia Pacific: The artificial heart-lung machine market in Asia Pacific is growing at a high rate due to the presence of many patients, increased government spending in the healthcare industry, and the increasing demand of high-tech treatment options. New economies within the region are also investing in more modern surgical facilities.

The region has challenges associated with growth including affordability problems, unequal distribution of technology, and lack of highly trained cardiac surgeons in some countries. All these obstacles may impede adoption in rural or resource-constrained regions.

• Germany Artificial Heart Lung Machines Market Insights:

China is the leader in this region due to a great number of investments in healthcare modernization, the development of specialized hospitals, and the increase in the number of complex cardiac surgical operations. It is the most important demand unit in Asia Pacific as it is large and increasingly interested in medical technology.

Artificial Heart Lung Machines Market Report Scope:

Attribute	Details
Market Size 2025	USD 413.66 Million
Projected Market Size 2035	USD 712.25 Million
CAGR Growth Rate	5.6% (2025-2035)
Base year for estimation	2024
Forecast period	2025 – 2035
Market representation	Revenue in USD Million & CAGR from 2025 to 2035
Regional scope	North America - U.S. and Canada Europe – Germany, U.K., France, Russia, Italy, Spain, Netherlands, and Rest of Europe Asia Pacific – China, India, Japan, Australia, Indonesia, Malaysia, South Korea, and Rest of Asia-Pacific Latin America - Brazil, Mexico, Argentina, and Rest of Latin America Middle East & Africa – GCC, Israel, South Africa, and Rest of Middle East & Africa
Company Landscape	Market Share Analysis of Companies Heat Map Analysis Company Overview, Product Types Overview Financial Information, Key Highlights Business Strategies Overview SWOT Analysis
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Value Added Data Infosets	Besides fundamental market insights such as the size of the market, growth rate, segmentation, regional study, and key players, our reports carry value-added data sets such as trade flow (import-export) analysis, production and consumption overview, price trend evaluation, supply and value chain mapping, and raw material availability. Moreover, we provide strategic tools as PESTLE and Porter’s Five Forces analysis, examination of the regulatory landscape, as well as monitoring of technology and innovation thereby providing a comprehensive overview which facilitates sensible and anticipatory decision-making.

Segmentation:

By Product Type:

• Component
  • Pumps
  • Cannulas & Tubing Sets
  • Monitoring Systems
  • Others
• Function
  • Oxygenation Support
  • Blood Circulation
  • Temperature Regulation
  • Others

By Technology:

• Mechanical Systems
• Electromechanical Systems
• Computer-Assisted Systems
• Miniaturized Systems
• Others

By Portability:

• Stationary Systems
• Portable Systems
• Compact Systems

By Application:

• Cardiac Surgery
• Lung Transplantation
• Acute Respiratory Failure
• Pediatric Cardiac Procedures
• Emergency Resuscitation
• Others

By End User:

• Hospitals & Clinics
• Ambulatory Surgical Centers
• Research & Academic Institutions
• Military Medical Units
• Veterinary Clinics
• Others

By Region:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • U.K.
  • France
  • Russia
  • Italy
  • Spain
  • Netherlands
  • Rest of Europe
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • Indonesia
  • Malaysia
  • South Korea
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
• Middle East & Africa
  • GCC
  • Israel
  • South Africa
  • Rest of Middle East & Africa

Manufacturers may consider producing cost-effective, biocompatible systems that will minimize risks during surgeries to speed up the development of the artificial heart-lung machine market. Increasing manufacturing capacity in new locations will enhance accessibility and service increasing patient demand.

Training programs conducted in collaboration with hospitals can help to increase adoption, and the consistent innovation in compact and portable designs will expand the use of this type of device to the territory of conventional surgical facilities. The key players operating in the artificial heart lung machines market include, LivaNova, Inc., NIPRO, Getinge, and others.

Artificial Heart Lung Machines Market Companies:

• Medtronic
• LivaNova, Inc.
• Terumo Corporation
• Getinge
• Braile Biomédica
• Edwards Lifesciences Corporation
• NIPRO
• Fresenius Medical Care AG
• MAQUET
• BiVACOR Inc.
• MERA
• Technowood International Pte. Ltd
• Elite Lifecare
• Hemovent GmbH
• CARMAT

View an Additional List of Companies in the Artificial Heart Lung Machines Market

• In 2025, LivaNova has begun commercial rollout of its Essenz Perfusion System in China, increasing the presence of its innovative cardiopulmonary solutions in the market. The Essenz system is aimed at improving quality and safety in cardiac operations, and providing better patient results. The introduction is also an indicator of how LivaNova aims to offer innovative technologies to help medical professionals deliver high-quality care. The launch of the Essenz system in China can be regarded as a serious move towards the global expansion strategy of LivaNova.
• In 2024, Medtronic has also announced that its VitalFlow ECMO system has been CE Mark approved and this has been a huge development in the extracorporeal membrane oxygenation technology. It is an all-in-one system to promote patient care in cardiac and respiratory support processes. VitalFlow ECMO system is designed to enhance clinical outcomes by offering effective and efficient patient support throughout critical intervention.

Analyst View:

The market of artificial heart-lung machine is poised to steadily increase, as the cases of cardiovascular diseases increase and the volumes of surgeries continue to grow all across the globe. New biocompatible materials and portable systems are improving safety and access. Although cost is a challenge, more healthcare investments and infrastructure construction is clearing these hurdles. In general, both existing and new manufacturers are possibly to find strong opportunities in the market.

Analysis of Sources:

Primary Sources:

• In-depth interviews
• Company-specific data
• Surveys and questionnaires
• Focus group discussions (FGDs)
• Others

Secondary Sources:

• National Institute of Health
• ASAIO Journal
• Frontiers
• The Journal of Heart and Lung Transplantation
• Others

More Related Reports

Artificial Intelligence in Transportation Market
Artificial Intelligence (AI) in Agriculture Market
Artificial Intelligence in Healthcare Market
Artificial Intelligence (AI) sensor Market
Artificial Intelligence in Education System Market

Company Name	Product Portfolio
Medtronic	Heart lung machine, Pediatric cannulae, Adult oxygenators and Others
LivaNova, Inc.	Heart-lung machine, Blood-Gas monitoring system, and Others
Terumo Corporation	Advanced perfusion heart lung machine
Braile Biomédica	Cardiopulmonary bypass machine
Fresenius Medical Care AG	ECMO heart and lung system